B16-GM irradiated tumor cells

B16-GM irradiated tumor cells represent an experimental cellular immunotherapy and cancer vaccine model used extensively in preclinical oncology research. This modality consists of B16 mouse melanoma cells that have been genetically engineered, typically via retroviral-mediated gene transfer, to secrete the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). The cells are subsequently irradiated to terminate their proliferative capacity while maintaining their metabolic activity and ability to secrete GM-CSF for a limited period. When administered subcutaneously, the vaccine provides a localized, sustained release of GM-CSF that recruits and activates host dendritic cells and other antigen-presenting cells to the vaccination site. these cells then ingest tumor-associated antigens from the irradiated B16 cells and migrate to regional lymph nodes to prime a potent, systemic, and long-lasting anti-tumor immune response involving both CD4+ and CD8+ T lymphocytes. This research tool has been instrumental in defining the mechanisms of GM-CSF-mediated tumor immunity and informed the development of human GVAX-style vaccines.

Other names

irradiated GM-CSF-secreting B16 melanoma cellsB16-GM cellsB-16-GM cellsB 16-GM cellsGM-CSF-secreting B16 tumor cellsirradiated B16-GM cells